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Summary
The balance between type 1 and 2 T helper cell cytokine production plays an important role in
several animal models ofautoimmunity, and skewed patterns of cytokine expression have been
described in human inflammatory diseases. Many cytokines activate signal transducer and activa-
tion of transcription (STAT) transcription factors, which, in turn, activate transcription ofinflam-
matory effector genes. We used mononuclear cell priming cultures and inflammatory synovial
fluids (SFs) derived from arthritis patients to examine the regulation of cytokine production and
STAT activity by an inflammatory synovial microenvironment. Exposure to SFs during prim-
ing resulted in an 81% inhibition of interferon (IFN)-'y, but not interleukin (IL) 4, production
by effector cells generated in priming cultures. SF suppression was mediated by IL-4 and IL-10
and inhibition ofIL-12 expression, and it was reversed in a dominant fashion by exogenous IL-12.
SFs blocked the sustained activity of transcription factor Statl, but not Stat3, during the prim-
ing period, and Statl activity was differentially regulated by cytokines in parallel with their pos-
itive or negative regulation of IFN-y production. Active Stat3, but not Statl, was detected in
cells from inflamed joints. These results suggest a role for altered balance of Statl and Stat3
transcriptional activity in the regulation of T cell differentiation and in the pathogenesis ofin-
flammatory synovitis.
A ctivation of cells and subsequent secretion ofcytokines
~'~play an important role in autoimmune and inflamma-
tory diseases. Predominant expression of either Thl (IFN-y
and lymphotoxin) or Th2 (IL-4, IL-5, IL-6, and IL-10) cy-
tokines has been associated with active inflammation (1) . For
example, Thl cytokines contribute to the pathogenesis ofex-
perimental allergic encephalitis (2) and collagen-induced ar-
thritis (3), whereas elevated Th2 cytokine production has
been associated with inflammatory bowel disease (4), autoan-
tibody production (5), and chronic arthritis associated with
the caprine arthritis-encephalitis virus (CAEV)' (6) . Patterns
ofcytokine expression during an immune response are con-
trolled by a complex regulatory network that uses cytokines
and factors derived from accessory cells and T cells (7). IL-12
and IFN-y are the primary stimulators of Thl responses,
whereas Th2 cytokine production is stimulated by IL-4,
IL-10, and E series prostaglandins (PGEs). There is little in-
'Abbreviations used in this paper: CAEV, caprine arthritis-encephalitis virus;
CM, complete medium; MNC, mononuclear cell; mRNA, messenger
RNA; PGE, E series prostaglandin; SF, synovial fluid; SIF, serum-induc-
ible factor; STAT, signal transductors and activators of transcription.
formation available concerning which of these factors is
important in regulating cytokine expression in inflamma-
tory diseases.
Many cytokines that regulate immune responses activate
specific members ofthe STAT (signal transducers and acti-
vators oftranscription) family of transcription factors (8, 9).
STATs exhibit differential binding to target sequences present
in gene promoters, and the pattern of STATs that become
activated determines, at leastin part, patterns ofgene expres-
sion and the phenotype ofactivated cells. In experiments us-
ing cell lines, purified cytokines preferentially activate partic-
ular STATs by inducing tyrosine phosphorylation of STATs
by cytokine receptor-associated Jak kinaes. For example,
IFN-y preferentially activates Statl, and IL-6 preferentially
activates Stat3 (8). However, regulation of STATs in a more
physiological setting is more complex and may involve reg-
ulation of STAT dephosphorylation (10) and serine phosphor-
ylation (11) as well as regulation ofJak kinase activity by ad-
ditional ligands (12). Thus, the pattern of activated STATs
may reveal information about integrated cellular responses
to multiple ligands.
Chronic inflammatory arthritis (synovitis) in humans rep-
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tokines are expressed and are likely to contribute to patho-
genesis (13) . The presence of high levels of Th2 cytokines
and regulators, such as IL-10, PGEs, and TGF-R, coupled
with the low levels of IFN-'Y protein in actively inflamed
joints (13-17), suggests that down-regulation of Thl cy-
tokines may occur during synovitis (16). We studied the
regulation of cytokine production and STAT activity using
an in vitro priming system in which mononuclear cells
(MNC) from peripheral blood are exposed to synovial flu-
ids (SFs) from patients with inflammatory arthritis. The aim
is to reproduce existing conditions when blood mononu-
clear cells enter an inflamed joint and are exposed to a com-
plex inflammatory microenvironment. Culture with SFs re-
sulted in the inhibition of Statl activity, with concomitant
polarization of cytokine production toward a Th2 pheno-
type.
Materials and Methods
Cell Culture and Flow Cytometry.
￿
Ficoll density gradient-puri-
fied peripheral blood MNC obtained from disease-free volunteers
was stimulated with 1.3 Htg/ml PHA in complete medium (CM;
RPMI 1640 supplemented with glutamine and 5% fetal bovine
serum) . SFs or plasma controls were added at a final concentra-
tion of 30% at the initiation of culture. After 7 d, effector cells
were harvestedand washed, and 1.8 X 106 cells were restimulated
in CM with 10 N.g/ml PHA. After culture, >90% of cells were
viable, as assessed by trypan blue and propidium iodide staining,
and cell surfacephenotype was analyzed using flow cytometry. The
following purified mAbs were used. T cell markers: 4135 (anti-
CD3), 13138.2 (anti-CD4), and 139.11 (anti-CD8); B cells: J4.119
(anti-CD19) andBLy.1 (anti-CD20); monocytes: IV.3 (anti-CD32
monocyte-specific epitope) and RM052 (anti-CD14); NK cells:
3G8 (anti-CD16) and T1 .99 (anti-CD56). mAbs were purchased
from Amac, Inc. (Westbrook, ME), except for 4135 (Boehringer
Mannheim Corp., Indianapolis, IN) and IV.3 (Medarex, New
Lebanon, NH). IgG1 (MOPC 21) and IgG2a (UPC10) isotype
controls were obtained from Sigma Chemical Co. (St. Louis, MO).
SFs.
￿
SFs were obtained, afterreceivinginformed consent, from
patients with seropositive definite or classic rheumatoid arthritis
(11 SFs), or with chronic seronegative inflammatory arthritis (6
SFs), by the patients' physicians for medically indicated reasons.
The protocol for obtaining research samples has been approved
by the Institutional Review Board. SFs were handled using sterile
Results
Table 1.
￿
Cytokine Secretion and Phenotype ofPrimed Blood Mononuclear Cells
IFN-y IL-4
Pg/ml
Fresh MNC
￿
420 ± 40
￿
30 -+ 10
Primed MNC
￿
2,900 ± 840
￿
340 ± 130
(day 7)
technique and centrifuged for 10 min at 10,000 g to remove cells
and particulate debris; aliquots were stored at -80°C.
ELISA.
￿
Indirect ELISA was performed using specific mono-
clonal capture antibodies anti-IFN-y (Genzyme, Cambridge, MA)
and MP4-25D2 (anti-IL-4; PharMingen, San Diego, CA) and sec-
ondary antibodies anti-IFN-y (R&D Systems, Minneapolis, MN)
and 8D4.8 (anti-IL-4; PharMingen), using the protocol provided
by PharMingen. All samples were tested in duplicate. The values
in Table 1 represent cytokine secretion per 106 CD3+ cells, which
was calculated using the following formula: (measured cytokine
secretion per 106 MNC - percentage of CD3+ cells) X 100 =
cytokine secretion per 106 CD3+ cells.
cDNA Preparation and PCR.
￿
RNA was prepared using RNA-
zol (TM Cinna Scientific, Friendswood, TX), and cDNA was ob-
tained using 1 l,tg oftotal cellular RNA and avian myeloblastosis
virus reverse transcriptase (Invitrogen, San Diego, CA). 1 or 5%
of each cDNA was subjected to 25 (glyceraldehyde-3-phosphate
dehydrogenase), 30 (IL-2), or 35 (IL-12 p40) cycles of PCR am-
plification, with 1 min denaturation at 94°C, 1 min annealing at
60°C, and 1.5 min extension at 72°C. The GAPDH andIL-2 prim-
ersspan introns and corresponds to primers provided by Stratagene
(LaJolla, CA), and the IL-12 p40primer sequences are 5' GAA-
GATGGTATCACCTGGACand5'GAAGAAGCTGCTGGT-
GTAGT. PCR resulted in single detectable amplification prod-
ucts of the correct size containing appropriate restriction sites.
Amplification was determined to be in the linear range by using
serial dilutions ofcDNA and different cycle numbers.
DNA-binding Assays.
￿
Cell extracts were prepared, and 8 ILgof
extract was assayed for binding to aradiolabeled hSIE oligonucleo-
tide (containing a STAT bindingsite; reference 18) or to a control
Sp1 oligonucleotide using gel shift assays, as previously described
(17, 18).
SFs Skew Cytokine Production toward a Th2 Pattern.
￿
Prim-
ing oflymphocytes or MNC results in the generation ofef-
fector cells that exhibit an enhanced capacity to produce
both Thl and Th2 cytokines. Addition of regulatory fac-
tors during the priming period results in skewing of cyto-
kine production toward a Thl or Th2 pattern (7). Table 1
shows the MNC cell surface phenotype and cytokine pro-
duction, in our system, before and after 7 d ofpriming cul-
ture. Priming was effective, because restimulation of effec-
tor cells, which were predominantly lymphocytes, on day 7
resulted in sevenfold more IFN-y production and 11-fold
CD3+
54±5
78±3
Freshly isolated MNC or day7 effector cells were analyzed forcell surface marker expression using flow cytometry. 1.8 X 106 cells were stimulated
in CM with 10 Ltg/ml PHA, culture supernatants were collected after 24 h, and cytokine concentrations were measured by ELISA; values shown
have been normalized according to numbers ofCD3+ cells (see Materials and Methods). The results shown are derived from at least sevenindepen-
dent experiments.
*Non-CD3+ or -CD19+ day 7 cells expressed monocyte (<5%) and NK cell (<3%) markers.
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CD4+
￿
CD19+
￿
CD3+ or CD19+*
40±6 11±2 68±6
58 - !- 4 14±2 94 - ! - 4Figure 1.
￿
Regulation ofIFN-y and IL-4
secretion by SFs and cytokines. Priming
cultures were carried out (A) in CM plus
30% plasma (control) or 30% FS. In (B),
CM was supplemented with 30% plasma
and TGF-(3 (20 ng/ml), IL-10 (20 ng/
ml), PGE2 (10-6 M) and 8-Br-CAMP (1
mM), IL-12 (20 ng/ml), control IgG (20
N.g/rnl), anti-IL-12 IgG (20 Ltg/ml), or
anti-IFN-y IgG (20 ltg/ml). On day 7,
cells were washed and analyzed by flow
cytometry; 1.8 X 106 effector cells, con-
taining comparable numbers of CD3+ and
CD4+ cells, were restimulated in CM with
10 N.g/ml PHA. Culture supernatants were
harvested after 24 h, and cytokine levels
were assayed by ELISA. Cell viability
Anti- Anti-
￿
(>90%) and cell surface phenotype (the
cAMP
￿
IL-12
￿
IFN-y
￿
percentage ofcells that were CD3- , CD4+,
CD8+, and CD19+) were comparable; SFs
decreased cell yield by 20%. Results obtained with the five most extensively tested SFs are shown; SFs 1 and 4 were obtained from patients seropositive
for rheumatoid factor, whereas SFs 2, 3, and 5 were obtained from seronegative patients. 16 out of 17 SFs (11 patients seropositive for rheumatoid factor)
screened inhibited IFN--y production by >60%. Data are shown as mean relative secretion ofcytokines i- SD compared with the control culture in each
experiment. The values are based on a minimum of (A) five or (B) three experiments with different donors.
v
J
a
m
z
0
0
U m
Co
Control SR SF2 SF3 SF4 SFS
v
J
a
m r z
0
0
U
a1
rn
220
200
180
160
140
120
100
8o
60
40
20
0
1827
￿
Wang et al.
Control
more IL-4 production than stimulation of freshly isolated
cells. The effect of SFs, obtained from patients with active
inflammatory arthritis, on the balance of cytokine produc-
tion was tested next. Treatment with SFs resulted in a mean
81% inhibition of IFN--y production (Fig. 1 A; five repre-
sentative SFs out of 17 tested are shown) and a parallel in-
hibition ofIFN-y messenger RNA (mRNA) levels (datanot
shown) . In contrast, priming for IL-4 synthesis was largely
unaffected, because SF-treated cells secreted 49-86% (mean
74%) as much IL-4 as control cells. Thus, treatment with SFs
resulted in the preferential inhibition of IFN--y production,
which is typical of a Th2 response.
Inflammatory SFs typically contain high levels of factors
that can promote Th2 responses, such as IL-10, PGEs, and
TGF-R (13, 14) and low levels ofIFN-'1' (15-17) ; many con-
tain no detectable IL-12 (Ivashkiv, L.-B., unpublished data).
Next, to test whether any ofthese agents play an important
or dominant role in regulating IFN--y production in our
system, we added individual agents or neutralizing antibodies
to the priming cultures (Fig. 1 B) . The inhibitory effect of
SFs on IFN--y production was mimicked by adding IL-10
or cAMP, or by neutralizing either IFN-'Y or IL-12. Thus, no
one regulatory factor was dominant, and several different
factors or mechanisms could mediate the SF effect.
Role ofIL-4, IL-10, and IL-12 in Regulation ofIFN-y Pro-
duction by SFs. SFs contain a complex mixture of cytokines
that may have synergistic or antagonistic effects. Furthermore,
cytokines detected in SFs by immunological methods may
be denatured or complexed to inhibitors and have no bio-
activity (16, 19). Therefore, rather than measuring cytokine
levels or fractionating SFs to attempt to identify active mol-
ecules, we used neutralizing antibodies to test the effect of
blocking cytokine activity during the priming period.
Neutralization of both IL-10 and IL-4 during priming was
required to reverse the SF inhibition o£ IFN--y production
(Fig. 2 A). As expected (7), priming for IL-4 production in
TGF-(i IL-10 PGE IL-12 IgG
both control and SF-treated cultures depended on the pres-
ence of IL-4 during the priming period (Fig. 2 B).
IL-10 is expressed in inflamed synovium (14) and inhib-
its production of several accessory cell-derived cytokines,
including the Thl stimulatory cytokine IL-12 (20) . We in-
vestigated whether SF treatment resulted in a deficit in en-
dogenous IL-12 activity in priming cultures. SFs specifically
suppressed induction of IL-12 mRNA during initiation of
priming cultures, because treatment with SFs resulted in sig-
nificantly lower levels of IL-12 but not IL-2 mRNA 3 h af-
ter stimulation (Fig. 3) . Addition of exogenous IL-12 to
control cultures resulted in a modest stimulation of IFN-y
production (Figs. 1 B and 2 A), probably because endoge-
nously produced IL-12 is present at near saturating levels in
our culture system. In contrast, addition ofexogenous IL-12
to SF-treated cultures resulted in a dramatic ninefold in-
duction of IFN--y production and a reversal of SF inhibi-
tion (Fig. 2, C and D) . Taken together, these results show
that SF treatment resulted in a relative deficit in IL-12 ac-
tivity. Our results demonstrate that SFs regulated priming
by modulating expression of several regulatory cytokines
during the priming period.
Parallel Regulation of Stat1 Activity and Primingfor IFN--y
Production. Because many ofthe cytokines that regulate T
cell differentiation activate STATs, we investigated the ac-
tivation of STAT DNA binding activity during priming
cultures by using gel shift assays. Binding of three com-
plexes of similar mobility to the hSIE oligonucleotide (18)
was induced in control cultures, where priming for both
IFN--y and IL-4 production occurs (Fig. 4, A, lane 4, and
C, lane 3). DNA binding was specific for the STAT se-
quence within the hSIE, derived predominantly from T
cells, and was dependent on tyrosine phosphorylation (data
not shown) . STAT DNA binding activity was not detected
until -1 d after stimulation; it peaked at 1-2 d and per-
sisted over at least 3 d of priming culture (Fig. 4, A, lanesFD
0
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1-4, and C, lanes 1-4) . This result contrasts with the previ-
ously described rapid activation ofSTATs after treatment
with high concentrations ofpurified cytokines (8, 9), which
we could reproduce in our system (Fig . 4 A, lanes 5-7) .
The most straightforward interpretation of these data is that
the initial priming stimulation with PHA does not activate
Figure 3 .
￿
Regulation ofIL-2 and IL-12 mRNA levels by SFs . Periph-
eral blood MNCs were stimulated with 1 .3 N.g/ml PHA, and cells were
harvested after 3 h, RNA extracted, and reverse transcribed into cDNA .
IL-2, IL-12 p40 subunit, and mRNA levels were compared using senu-
quantitative PCR, as described in Materials and Methods. For each sam-
ple, two different quantities ofcDNA (5 and 1% ofcDNA obtained using
1 N,g ofRNA) were subjected to PCR .
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Figure 2 .
￿
Role ofIL-4, IL-10, and IL-12
in regulation ofcytokine secretion by SFs.
(A and B) Cells were primed and cultured
with SFs and neutralizing IgG to IL-10
(20 Ltg/ml) or IL-4 (20 l.tg/ml) . Control
IgG was used to achieve a total IgG con-
centration of 40 Wg/ml in each culture .
Results obtained with two representative
SFs are shown- (C and D) IL-12 (20 ng/
ml) was added at initiation ofcultures . Cell
surface phenotype, viability, and yield were
comparable in all cultures . The values for
relative cytokine secretion are based on
SF5
￿
three independent experiments .
STATs, but subsequent production of cytokines during cul-
ture results in a delayed activation .
The hSIE oligonucleotide used in our studies preferen-
tially binds protein complexes that contain Statl and Stat3,
termed serum-inducible factor (SIF) A (upper complex, which
contains Stat3), SIF-B (middle complex, which contains
both Stat3 and Statl), and SIF-C (lower complex, which is a
homodimer of Statl) (18) . Because the STAT complexes
induced during priming had an identical mobility to SIF-A,
-B, and -C (data not shown), we tested whether these com-
plexes reacted with specific antisera against Statl or Stat3 (18)
in supershift experiments (Fig. 4 B) . The lower two com-
plexes reacted with the Statl antiserum, whereas the upper
two complexes reacted with the Stat3 antiserum . Thus, prim-
ing resulted in the activation of Statl and Stat3, and the
complexes we have detected probably correspond to SIF-A,
-B, and -C . Interestingly, treatment with SFs, which sup-
pressed priming for IFN-y but not IL-4 production (Fig . 1
A), resulted in the preferential suppression of the lower two
complexes, which contain Statl, throughout the time course
of the experiment (Figs . 4 C and 5 A) . The inhibition of
Statl activity was not secondary to down-regulation of
Statl protein levels (data not shown) and thus reflected reg-
ulation ofDNA binding.
We next investigated the relationship between successful
priming for IFN-y production and the activity of Statl
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Regulation of STAT DNA binding activity during priming .
Cells were harvested at the indicated time points, and 8 ltg ofcell extract
was assayed for binding to a radiolabeled hSIE oligonucleotide (contain-
ing a STAT binding site ; reference 18) or to a control Spl oligonucleotide
using gel shift assays . Representative experiments are shown . (A) IFN-y
(100 U/ml) was added in lanes 5-7 . (B) 1 p,l of a 1 : 10 dilution ofspecific
anti-Statl or and-Stat3 antiserum (18) was incubated with extracts (ob-
tained 24 h after PHA stimulation) for 15 min before adding radiolabeled
probe . (C) SF was used at 30% final concentration .
during the priming period. IL-12, IFN-y, and antibodies to
IL-4 and IL-10, which blocked SF inhibition of IFN-y
production (Fig. 2 and data not shown), also blocked SF
inhibition of Statl activity (Fig . 5 A, lanes 1-12) . Further-
more, treatments that mimicked SF inhibition of IFN-y
production, such as neutralization of IFN-y or IL-12, or
addition of CAMP (Fig . 1 B), also inhibited Statl activity
(Fig . 5 A, lanes 13-15) but did not affect Statl protein lev-
els (data not shown) . These results demonstrate that several
factors differentially regulated the delayed phase of Statl
activity in parallel with the differential regulation of Thl
and Th2 responses .
Pattern ofSTAT Activity during Synovitis .
￿
We investigated
whether the pattern of STAT DNA binding activity de-
tected in SF-treated cultures reflected the pattern ofSTAT
activity in vivo during synovial inflammation . Extracts pre-
pared from cells freshly isolated from joint effusions of pa-
tients with inflammatory arthritis, contained predominantly
Stat3 but not Statl DNA binding activity (Fig . 5 B) . This is
consistent with the inability of several groups, including ours,
to detect IFN-y protein in inflammatory arthritis (15-17) .
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Figure 5 .
￿
Modulation of STAT DNA binding activity by SFs and in-
flammatory stimuli . (A) Extracts from cells primed for 2 d in the presence
of the indicated stimuli were assayed for binding to a radiolabeled hSIE
oligonucleotide (18) . The SFs, cytokines, and neutralizing antibodies
were used as described in the legends to Figs. 1 and 2 . (B) hSIE binding
by control extracts from IFN-y-stimulated monocytes (which contain
Statl ; reference 17) was compared with binding by extracts from synovial
cells freshly isolated from inflamedjoint effusions .A representative extract
from the six extracts tested is shown. 1 N .1 of a 1 :10 dilution of each spe-
cific antiserum (18) was used .
In contrast, in delayed-type hypersensitivity, a Thl response,
active Statl is present in skin lesions (21) .
Discussion
Relatively little is known about the mechanisms that
regulate the balance of Thl versus Th2 cytokine produc-
tion during chronic human inflammatory diseases such as
synovitis . T cells that enter inflamed synovium are exposed
to multiple agonists and antagonists that preexist in the
joint or are produced by cells as theybecome activated . We
have investigated mechanisms regulating cytokine produc-
tion using a culture system that attempts to mimic the com-
plexity of regulation in vivo . Our results show that soluble
synovial inflammatory mediators specifically inhibit transcrip-
tion factor Statl in PHA-activated T cells . A functional cor-
relate of Statl suppression is the inhibition of development
of effector T cells that produce high levels ofIFN-y . Statl
activity and IFN-y production were regulated in parallel by
a cytokine regulatory network that involved IL-4, IL-10,
and IL-12 and was modulated by SFs .
IL-4, IL-10, and IL-12 have previously been shown to
regulate Thl versus Th2 cytokine production (7) . In many
systems, IL-4 alone is sufficient to induce a Th2 response and
is dominant over IL-12 (7, 22) . SF suppression of IFN-y
production required IL-10 (and inhibition of IL-12) in ad-dition to IL-4, and exogenous IL-12 restored IFN-y pro-
duction in a dominant fashion. These results suggest that ac-
cessory cell-derived factors, such as IL-10 and IL-12, may
play an important or dominant role in the regulation of T
cell cytokine production during synovial inflammation. The
imbalance in cytokine production we have described reflects
the pattern ofcytokine expression in chronic human synovi-
tis and CAEV-associated arthritis (6, 13). Th2 cytokines can
contribute to pathogenesis by driving synovial production
of antibodies and formation ofimmune complexes, or by in-
ducing expression of metalloproteases (23) and inflamma-
tory mediators, such as soluble CD23 (24) . Alternatively, Th2
cytokines may contribute to pathogenesis by suppressing Th1-
mediated clearance of (auto)antigens or inappropriately ac-
tivated cells (25) .
Statl activity in priming cultures was differentially regu-
lated by SFs, cAMP, IL-4, IFN-y, and IL-12 (Figs. 4 and 5;
Wang, F., unpublished data). This antagonistic regulation
ofa STAT factor by several opposing cytokines represents a
novel mechanism for modulating STAT signaling and al-
lows Statl to function as a cellular "node" that integrates
multiple signals into a transcriptional response. The block
of Statl activity could be achieved by preventing produc-
tion of the cytokine, which directly activates Statl, inter-
ruption of intracellular signals upstream of Statl activation
(12) or activation ofStatl-specific tyrosine phosphatases. At
this time, it is not clear which cytokine directly activates
Statl in priming cultures. Statl can be activated by many
cytokines, including IFN-'Y, IFN-a, IL-2, IL-6, platelet-
derived growth factor, and epidermal growth factor (8, 9).
The absence ofStatl activity in the presence ofneutralizing
anti-IFN-y antibodies (Fig. 5 A) suggests that IFN-y may
be the responsible cytokine. However, persistence of Statl
activity over several days would be atypical after IFN-y ac-
tivation, and culture supernatants contained very low levels
of IFN-y immuno- and bioactivity (Ivashkiv, L. B., unpub-
lished data). This suggests that IFN-y may act indirectly or
that alternative mechanisms, such as regulation ofStatl de-
phosphorylation, may be important.
Our previous work showed that SFs directly activate, in
monocytes, a DNA-binding complex that contains Stat3 but
not Statl (17). The new results demonstrate that SFs use a dif-
ferent mechanism, namely, inhibition of Statl, to achieve a
similar skewing of the balance of transcriptional activity in
activated T cells. Stat3 binds weakly to the Statl target se-
quences in several promoters and does not activate transcrip-
tion of promoters containing these sites in cotransfection
assays (reference 26; Zhong, Z., unpublished data). Thus, SF-
treated lymphocytes will probably express Stat3 target genes
in the absence ofexpression ofgenes whose transcription de-
pends on Statl. The altered balance of Stat3 and Statl tran-
scriptional activity correlates well with the altered balance
of cytokine production and was also detected in cells from
inflamed joints (Fig. 5 B). These results suggest a role for
Statl and Stat3 in the regulation of the development of Th
phenotype and in the pathogenesis ofinflammatory synovitis.
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